deltatrials
Completed INTERVENTIONAL NCT07266818

A Clinical Trial of MK-1167 in Healthy Adults (MK-1167-010)

A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Effect of MK-1167 on QTc in Healthy Adult Participants

Sponsor: Merck Sharp & Dohme LLC

Conditions Healthy
Interventions MK-1167 Placebo
Updated 3 times since 2026 Last updated: Apr 24, 2026 Started: Dec 18, 2025 Primary completion: Apr 9, 2026 Completion: Apr 9, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07266818, this observational or N/A phase trial focuses on Healthy and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 3 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2026 – ~Feb 2026 · 31 days · monthly snapshotNot Yet Recruiting~Feb 2026 – ~May 2026 · 3 months · monthly snapshotActive Not RecruitingMay 4, 2026 – present · 4 months · daily APICompleted

Change History

3 versions recorded

  1. May 4, 2026 — Present [daily]

    Completed

    Status: Active Not Recruiting → Completed · Phase: PHASE1 → None

  2. Feb 2026 — May 2026 [monthly]

    Active Not Recruiting PHASE1

    Status: Not Yet Recruiting → Active Not Recruiting

  3. Jan 2026 — Feb 2026 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Dec 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

The goal of this trial is to learn about the safety of MK-1167 and if people tolerate it.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations